Loading patent…
AssigneeSasya Inc.
InventorsGoutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
Estimating the term…
The biological production of beta-hydroxyisovalerate (βHIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active βHIV metabolic pathway for the production of βHIV. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
A non-natural microorganism capable of producing beta-hydroxyisovalerate (βHIV), wherein the non-natural microorganism comprises a non-natural enzyme, wherein the non-natural enzyme has been modified or mutated to inncrease the ability of the enzyme to preferentially utilize α-ketoisocaproate as its substrate, and wherein the non-natural enzyme comprises one or more modifications or mutations at substrate-specificity positions corresponding to amino acids selected from N187, W210, V212, V217, L224, S226, I227, V228, P239, N241, Q251, I252, Q265, L289, L323, F336, F347, A361, G362, N363, F364, L367, F368, and F371, of any of SEQ ID NO:
A method of producing βHIV using a non-natural microorganism, the method comprising:
A composition comprising:
Dependencies are inferred from the claim text.